Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Syndax announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint of annualized FVC decline, and the company will not pursue further IPF development of the drug. The 145-patient trial showed a safety profile comparable to placebo with no new safety signals, but failed on efficacy.
Key figures
- Drug Name
- axatilimab (Niktimvo)
- Phase Of Trial
- Phase 2
- Sites
- 62
- Patients
- 145
- Countries
- 14
- Indication
- idiopathic pulmonary fibrosis (IPF)
- Trial name
- MAXPIRe (NCT06132256)
- Primary endpoint
- annualized rate of decline in FVC
- Development status
- Syndax will not advance axatilimab further in IPF
- Trial duration weeks
- 26
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.